These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12167390)

  • 21. Carvedilol: a review of its use in chronic heart failure.
    Keating GM; Jarvis B
    Drugs; 2003; 63(16):1697-741. PubMed ID: 12904089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Re-Examination of the BEST Trial Using Composite Outcomes, Including Emergency Department Visits.
    Shen L; Jhund PS; Mogensen UM; Køber L; Claggett B; Rogers JK; McMurray JJV
    JACC Heart Fail; 2017 Aug; 5(8):591-599. PubMed ID: 28774394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of atrial fibrillation by bucindolol is dependent on the beta₁389 Arg/Gly adrenergic receptor polymorphism.
    Aleong RG; Sauer WH; Davis G; Murphy GA; Port JD; Anand IS; Fiuzat M; O'Connor CM; Abraham WT; Liggett SB; Bristow MR
    JACC Heart Fail; 2013 Aug; 1(4):338-344. PubMed ID: 24159564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial.
    Bristow MR; Krause-Steinrauf H; Nuzzo R; Liang CS; Lindenfeld J; Lowes BD; Hattler B; Abraham WT; Olson L; Krueger S; Thaneemit-Chen S; Hare JM; Loeb HS; Domanski MJ; Eichhorn EJ; Zelis R; Lavori P
    Circulation; 2004 Sep; 110(11):1437-42. PubMed ID: 15337700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bucindolol, systolic blood pressure, and outcomes in systolic heart failure: a prespecified post hoc analysis of BEST.
    White M; Desai RV; Guichard JL; Mujib M; Aban IB; Ahmed MI; Feller MA; de Denus S; Ahmed A
    Can J Cardiol; 2012 May; 28(3):354-9. PubMed ID: 21982425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Are beta-blockers effective in patients who develop heart failure soon after myocardial infarction? A meta-regression analysis of randomised trials.
    Houghton T; Freemantle N; Cleland JG
    Eur J Heart Fail; 2000 Sep; 2(3):333-40. PubMed ID: 10938496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial.
    Domanski M; Krause-Steinrauf H; Deedwania P; Follmann D; Ghali JK; Gilbert E; Haffner S; Katz R; Lindenfeld J; Lowes BD; Martin W; McGrew F; Bristow MR;
    J Am Coll Cardiol; 2003 Sep; 42(5):914-22. PubMed ID: 12957443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced right ventricular ejection fraction and increased mortality in chronic systolic heart failure patients receiving β-blockers: insights from the BEST trial.
    Desai RV; Guichard JL; Mujib M; Ahmed MI; Feller MA; Fonarow GC; Meyer P; Iskandrian AE; Bogaard HJ; White M; Aban IB; Aronow WS; Deedwania P; Waagstein F; Ahmed A
    Int J Cardiol; 2013 Feb; 163(1):61-7. PubMed ID: 21704392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
    Lancet; 1997 Feb; 349(9049):375-80. PubMed ID: 9033462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do standardized beta-blocker titration protocols in heart failure improve compliance? The GESICA registry experience.
    Remme WJ
    Cardiovasc Drugs Ther; 2005 Mar; 19(2):99-101. PubMed ID: 16025226
    [No Abstract]   [Full Text] [Related]  

  • 31. [Aldosterone receptor blockade after acute myocardial infarction with heart failure].
    Bauersachs J; Ertl G
    Med Klin (Munich); 2006 Jun; 101(6):458-66. PubMed ID: 16767569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
    Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart.
    Willette RN; Mitchell MP; Ohlstein EH; Lukas MA; Ruffolo RR
    Pharmacology; 1998 Jan; 56(1):30-6. PubMed ID: 9467185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A personalized BEST: characterization of latent clinical classes of nonischemic heart failure that predict outcomes and response to bucindolol.
    Kao DP; Wagner BD; Robertson AD; Bristow MR; Lowes BD
    PLoS One; 2012; 7(11):e48184. PubMed ID: 23144856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction.
    Thune JJ; Signorovitch JE; Kober L; McMurray JJ; Swedberg K; Rouleau J; Maggioni A; Velazquez E; Califf R; Pfeffer MA; Solomon SD
    Eur J Heart Fail; 2011 Feb; 13(2):148-53. PubMed ID: 21037250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).
    Moiseyev VS; Põder P; Andrejevs N; Ruda MY; Golikov AP; Lazebnik LB; Kobalava ZD; Lehtonen LA; Laine T; Nieminen MS; Lie KI;
    Eur Heart J; 2002 Sep; 23(18):1422-32. PubMed ID: 12208222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Landmark study: the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study (CAPRICORN).
    Colucci WS
    Am J Cardiol; 2004 May; 93(9A):13B-6B. PubMed ID: 15144931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure.
    Parikh KS; Piccini JP
    Curr Heart Fail Rep; 2017 Dec; 14(6):529-535. PubMed ID: 28975475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Role of beta-blockers in the treatment of chronic heart heart failure].
    Czuriga I; Edes I
    Orv Hetil; 2001 Sep; 142(37):2005-12. PubMed ID: 11582731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imaging-Guided Cardioprotective Treatment in a Community Elderly Population of Stage B Heart Failure.
    Yang H; Negishi K; Wang Y; Nolan M; Marwick TH
    JACC Cardiovasc Imaging; 2017 Mar; 10(3):217-226. PubMed ID: 28279368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.